



## **NANOSONO Receives Notice of Allowance from U.S. Patent Office for its antimicrobial platform**

Yokneam-Israel (Jun, 2021)-- NANOSONO, Israeli-based startup which has developed groundbreaking antimicrobial technology against antibiotic-resistance bacteria, announced Today, that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its proven antimicrobial platform.

The two patents (No. US 10,995,011 / US 10,998,467), titled Composition of Metal Oxide Semiconductor Nanomaterials, and its Hemostatic Polymers, includes methods and approach of using metal oxide nanomaterials as bactericidal and wound healing accelerator.

"This is a major milestone for founding our novel-approach in the global marketplace. Said Ronen Sarusi CEO and founder of NANOSONO "Our evidence-based platform plays a pivotal role in preventing infections, cross-contaminations and pandemics. Every single year, tens of thousands people die in the US as a consequence of antibiotic-resistant infections. Our technology which can be incorporated in many objects in such highly infectious settings of hospitals and clinics, can be very useful in curbing the growing rate of infections, as well as reducing its enormous annual cost for the health system" he added.

### **Nanosono**

Nanosono was founded with a mission to offer game-changing antimicrobial solutions to fight against infections and diseases worldwide. Our team of 18 researchers, scientists and engineers work together to develop innovative state of the art and cost-effective antibacterial & antiviral solutions to multiple industries and products, which enable people everywhere to live safer, healthier lives.